Nishimura RA, Grantham JA, Connolly HM, et al. Low-output, low-gradi- ent aortic stenosis in patients with depressed left ventricular systolic func- tion: the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation. 2002;106:809 13. 2.3.5. Diagnostic Testing: Exercise Testing 1. Aviles RJ, Nishimura RA, Pellikka PA, et al. Utility of stress Doppler echocar- diography in patients undergoing percutaneous mitral balloon valvotomy. J Am Soc Echocardiogr. 2001;14:676 81. 2. Messika-Zeitoun D, Johnson BD, Nkomo V, et al. Cardiopulmonary exercise testing determination of functional capacity in mitral regur- gitation: physiologic and outcome implications. J Am Coll Cardiol. 2006;47:2521 7. 3. Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of quantita- tive exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation. 2005;112:I377 82. 4. Mar chaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis. Eur Heart J. 2010;31:1390 7. 5. Otto CM, Pearlman AS, Kraft CD, et al. Physiologic changes with maxi- mal exercise in asymptomatic valvular aortic stenosis assessed by Doppler echocardiography. J Am Coll Cardiol. 1992;20:1160 7. 6. Pierard LA, Lancellotti P. Stress testing in valve disease. Heart. 2007;93:766 72. 7. Magne J, Mahjoub H, Dulgheru R, et al. Left ventricular contrac- tile reserve in asymptomatic primary mitral regurgitation. Eur Heart J. 2014;35:1608 16. 8. Donal E, Mascle S, Brunet A, et al. Prediction of left ventricular ejection fraction 6 months after surgical correction of organic mitral regurgita- tion: the value of exercise echocardiography and deformation imaging. Eur Heart J Cardiovasc Imaging. 2012;13:922 30. 9. Wahi S, Haluska B, Pasquet A, et al. Exercise echocardiography predicts development of left ventricular dysfunction in medically and surgically treated patients with asymptomatic severe aortic regurgitation. Heart. 2000;84:606 14. 10. Gentry JL 3rd, Parikh PK, Alashi A, et al. Characteristics and outcomes in a contemporary group of patients with suspected significant mitral stenosis undergoing treadmill stress echocardiography. Circ Cardiovasc Imaging. 2019;12:e009062. 11. Lancellotti P, Dulgheru R, Go YY, et al. Stress echocardiography in patients with native valvular heart disease. Heart. 2018;104:807 13. 2.4. Basic Principles of Medical Therapy 1. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137 61. 2. Gati S, Malhotra A, Sharma S. Exercise recommendations in patients with valvular heart disease. Heart. 2019;105:106 10. 3. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596 646. 2.4.1. Secondary Prevention of Rheumatic Fever 1. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scien- tific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardio- vascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation. 2009;119:1541 51. 2.4.2. IE Prophylaxis 1. Glenny A-M, Oliver R, Roberts GJ, et al. Antibiotics for the prophy- laxis of bacterial endocarditis in dentistry. Cochrane Database Syst Rev. 2013;CD003813. 2. Mougeot FKB, Saunders SE, Brennan MT, et al. Associations between bacteremia from oral sources and distant-site infections: tooth brushing versus single tooth extraction. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:430 5. CLINICAL STATEMENTS AND GUIDELINES 3. Sherman-Weber S, Axelrod P, Suh B, et al. Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. Transpl Infect Dis. 2004;6:165 70. 4. Lockhart PB, Brennan MT, Sasser HC, et al. Bacteremia associated with toothbrushing and dental extraction. Circulation. 2008;117:3118 25. 5. Geist S-MRY, Fitzpatrick S, Geist JR. American Heart Association 2007 guidelines on prevention of infective endocarditis. J Mich Dent Assoc. 2007;89:50 6. 6. Duval X, Alla F, Hoen B, et al. Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis. Clin Infect Dis. 2006;42:e102 7. 7. The 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36:3036 7. 8. Horstkotte D, Rosin H, Friedrichs W, et al. Contribution for choosing the optimal prophylaxis of bacterial endocarditis. Eur Heart J. 1987;8:379 81. 9. Strom BL, Abrutyn E, Berlin JA, et al. Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med. 1998;129:761 9. 10. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocar- ditis. Recommendations by the American Heart Association. Circulation. 1997;96:358 66. 11. Guarner-Argente C, Shah P, Buchner A, et al. Use of antimicrobials for EUS-guided FNA of pancreatic cysts: a retrospective, comparative analysis. Gastrointest Endosc. 2011;74:81 6. 12. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocardi- tis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplin- ary Working Group. Circulation. 2007;116:1736 54. 13. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Manage- ment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:3036 7. 14. Prophylaxis Against Infective Endocarditis: Antimicrobial Prophylaxis Against Infective Endocarditis in Adults and Children Undergoing Inter- ventional Procedures. Available at: https://www.ncbi.nlm.nih.gov/books/ NBK554353/. Accessed October 12, 2020. 15. Thornhill MH, Gibson TB, Cutler E, et al. Antibiotic prophylaxis and inci- dence of endocarditis before and after the 2007 AHA recommendations. J Am Coll Cardiol. 2018;72:2443 54. 16. Desimone DC, Tleyjeh IM, Correa de Sa DD, et al. Incidence of infective endocarditis caused by viridans group streptococci before and after pub- lication of the 2007 American Heart Association s endocarditis prevention guidelines. Circulation. 2012;126:60 4. 17. Dayer MJ, Jones S, Prendergast B, et al. Incidence of infective endocardi- tis in England, 2000 13: a secular trend, interrupted time-series analysis. Lancet. 2015;385:1219 28. 18. Duval X, Delahaye F, Alla F, et al. Temporal trends in infective endocardi- tis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012;59:1968 76. 19. Pasquali SK, He X, Mohamad Z, et al. Trends in endocarditis hospitaliza- tions at US children s hospitals: impact of the 2007 American Heart As- sociation antibiotic prophylaxis guidelines. Am Heart J. 2012;163:894 9. 20. Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis in- cidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol. 2015;65:2070 6. 21. Thornhill MH, Dayer MJ, Forde JM, et al. Impact of the NICE guideline rec- ommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ. 2011;342:d2392. 22. Strom BL, Abrutyn E, Berlin JA, et al. Risk factors for infective endocarditis: oral hygiene and nondental exposures. Circulation. 2000;102:2842 8. 23. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, et al. Infective endo- carditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation. 2015;131:1566 74. 24. Mangner N, Woitek F, Haussig S, et al. Incidence, predictors, and outcome of patients developing infective endocarditis following transfemoral trans- catheter aortic valve replacement. J Am Coll Cardiol. 2016;67:2907 8. 25. Karavas AN, Filsoufi F, Mihaljevic T, et al. Risk factors and management of endocarditis after mitral valve repair. J Heart Valve Dis. 2002;11:660 4. 26. Gillinov AM, Faber CN, Sabik JF, et al. Endocarditis after mitral valve repair. Ann Thorac Surg. 2002;73:1813 6. 27. Botoman VA, Surawicz CM. Bacteremia with gastrointestinal endoscopic procedures. Gastrointest Endosc. 1986;32:342 6. 28. Low DE, Shoenut JP, Kennedy JK, et al. Risk of bacteremia with endoscopic sphincterotomy. Can J Surg. 1987;30:421 3. 29. Low DE, Shoenut JP, Kennedy JK, et al. Prospective assessment of risk of bacteremia with colonoscopy and polypectomy. Dig Dis Sci. 1987;32:1239 43. 30. Wolf JS, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179:1379 90. 2.4.3. Anticoagulation for AF in Patients With VHD 1. Pan K-L, Singer DE, Ovbiagele B, et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005835. 2. Lip GYH, Jensen M, Melgaard L, et al. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating valvular heart disease in a nationwide cohort study. Europace. 2019;21: 33 40. 3. Vora AN, Dai D, Matsuoka R, et al. Incidence, management, and associ- ated clinical outcomes of new-onset atrial fibrillation following transcath- eter aortic valve replacement: an analysis from the STS/ACC TVT registry. JACC Cardiovasc Interv. 2018;11:1746 56. 4. Seeger J, Gonska B, Rodewald C, et al. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. JACC Cardiovasc Interv. 2017;10:66 74. 5. Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:1566 76. 6. Mangner N, Crusius L, Haussig S, et al. Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implanta- tion and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation. Am J Cardiol. 2019;123:1134 41. 7. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran ver- sus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206 14. 8. De Caterina R, Renda G, Carnicelli AP, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Car- diol. 2017;69:1372 82. 9. Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the preven- tion of thromboembolism in patients with atrial fibrillation and biopros- thetic valves. Circulation. 2017;135:1273 5. 10. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with war- farin in patients with atrial fibrillation and valvular heart disease: find- ings from the Apixaban for Reduction in Stroke and Other Thromboem- bolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2015;132: 624 32. 11. Guimar es PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixa- ban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019;42:568 71. 12. Vinereanu D, Wang A, Mulder H, et al. Outcomes in anticoagulated pa- tients with atrial fibrillation and with mitral or aortic valve disease. Heart. 2018;104:1292 9. 13. Breithardt G, Baumgartner H, Berkowitz SD, et al. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart. 2016;102:1036 43. 14. Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease par- ticipating in the ROCKET AF trial. Eur Heart J. 2014;35:3377 85. 15. Siontis KC, Yao X, Gersh BJ, et al. Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves: a meta-analysis. Circulation. 2017;135:714 6. 16. Andrade JG, Meseguer E, Didier R, et al. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves. Ex- pert Rev Cardiovasc Ther. 2018;1 6. 17. Renda G, Ricci F, Giugliano RP, et al. Non-vitamin K antagonist oral antico- agulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol. 2017;69:1363 71. 18. Briasoulis A, Inampudi C, Akintoye E, et al. Safety and efficacy of novel oral anticoagulants versus warfarin in Medicare beneficiaries with atrial fibrillation and valvular heart disease. J Am Heart Assoc. 2018;7:e008773. CLINICAL STATEMENTS AND GUIDELINES 19. Philippart R, Brunet-Bernard A, Clementy N, et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost. 2016;115:1056 63. 20. Duraes AR, de Souza Roriz P, de Almeida Nunes B, et al. Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Manage- ment of Atrial Fibrillation Postoperatively: DAWA Pilot Study. Drugs R D. 2016;16:149 54. 21. Noseworthy PA, Yao X, Shah ND, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol. 2016;209:181 3. 22. Kim JY, Kim S-H, Myong J-P, et al. Outcomes of direct oral anticoagulants in patients with mitral stenosis. J Am Coll Cardiol. 2019;73:1123 31. 23. Dangas GD, Tijssen JGP, Wohrle J, et al. A controlled trial of rivaroxaban af- ter transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120 9. 2.5. Evaluation of Surgical and Interventional Risk 1. Edwards FH, Cohen DJ, O Brien SM, et al. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA Cardiol. 2016;1:46 52. 2. Pilgrim T, Franzone A, Stortecky S, et al. Predicting mortality after trans- catheter aortic valve replacement: external validation of the Transcatheter Valve Therapy registry model. Circ Cardiovasc Interv. 2017;10:e005481. 3. Greason KL, Eleid MF, Nkomo VT, et al. Predictors of 1-year mortality after transcatheter aortic valve replacement. J Card Surg. 2018;33:243 9. 4. Arsalan M, Weferling M, Hecker F, et al. TAVI risk scoring using established versus new scoring systems: role of the new STS/ACC model. EuroInter- vention. 2018;13:1520 6. 5. Kiani S, Kamioka N, Black GB, et al. Development of a risk score to predict new pacemaker implantation after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:2133 42. 6. Thourani VH, O Brien SM, Kelly JJ, et al. Development and application of a risk prediction model for in-hospital stroke after transcatheter aortic valve replacement: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac Surg. 2019;107:1097 103. 7. Lytwyn J, Stammers AN, Kehler DS, et al. The impact of frailty on func- tional survival in patients 1 year after cardiac surgery. J Thorac Cardiovasc Surg. 2017;154:1990 9. 8. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovas- cular care of older adults. J Am Coll Cardiol. 2014;63:747 62. 9. Schoenenberger AW, Moser A, Bertschi D, et al. Improvement of risk pre- diction after transcatheter aortic valve replacement by combining frailty with conventional risk scores. JACC Cardiovasc Interv. 2018;11:395 403. 10. Afilalo J, Lauck S, Kim DH, et al. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol. 2017;70:689 700. 11. Arnold SV, O Brien SM, Vemulapalli S, et al. Inclusion of functional status mea- sures in the risk adjustment of 30-day mortality after transcatheter aortic valve replacement: a report from the Society of Thoracic Surgeons/American College of Cardiology TVT Registry. JACC Cardiovasc Interv. 2018;11:581 9. 12. Arnold SV, Reynolds MR, Lei Y, et al. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Place- ment of Aortic Transcatheter Valve) trial. Circulation. 2014;129:2682 90. 13. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696 704. 14. Suri RM, Gulack BC, Brennan JM, et al. Outcomes of patients with severe chronic lung disease who are undergoing transcatheter aortic valve re- placement. Ann Thorac Surg. 2015;100:2136 45. 15. Thourani VH, Forcillo J, Beohar N, et al. Impact of preoperative chronic kidney disease in 2,531 high-risk and inoperable patients undergoing transcatheter aortic valve replacement in the PARTNER Trial. Ann Thorac Surg. 2016;102:1172 80. 16. Puri R, Iung B, Cohen DJ, et al. TAVI or no TAVI: identifying patients un- likely to benefit from transcatheter aortic valve implantation. Eur Heart J. 2016;37:2217 25. 17. Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol. 2014;64:172 81. 18. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mi- tral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64:182 92. 19. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307 18. 20. Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgi- cal mortality in the United States. N Engl J Med. 2002;346:1128 37. 21. Vemulapalli S, Carroll JD, Mack MJ, et al. Procedural volume and out- comes for transcatheter aortic-valve replacement. N Engl J Med. 2019;380:2541 50. 22. Carroll JD, Vemulapalli S, Dai D, et al. Procedural experience for transcath- eter aortic valve replacement and relation to outcomes: the STS/ACC TVT registry. J Am Coll Cardiol. 2017;70:29 41. 23. Russo MJ, McCabe JM, Thourani VH, et al. Case volume and outcomes af- ter TAVR with balloon-expandable prostheses: insights from TVT registry. J Am Coll Cardiol. 2019;73:427 40. 24. Bolling SF, Li S, O Brien SM, et al. Predictors of mitral valve repair: clinical and surgeon factors. Ann Thorac Surg. 2010;90:1904 11. 25. Badhwar V, Ofenloch JC, Rovin JD, et al. Noninferiority of closely moni- tored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients. Ann Thorac Surg. 2012;93:748 53. 26. Hart SA, Krasuski RA, Wang A, et al. Pulmonary hypertension and elevat- ed transpulmonary gradient in patients with mitral stenosis. J Heart Valve Dis. 2010;19:708 15. 27. Weiner MM, Hofer I, Lin H-M, et al. Relationship among surgical vol- ume, repair quality, and perioperative outcomes for repair of mitral in- sufficiency in a mitral valve reference center. J Thorac Cardiovasc Surg. 2014;148:2021 6. 28. LaPar DJ, Ailawadi G, Isbell JM, et al. Mitral valve repair rates correlate with surgeon and institutional experience. J Thorac Cardiovasc Surg. 2014;148:995 1003. 29. Kilic A, Shah AS, Conte JV, et al. Operative outcomes in mitral valve sur- gery: combined effect of surgeon and hospital volume in a population- based analysis. J Thorac Cardiovasc Surg. 2013;146:638 46. 30. Gammie JS, O Brien SM, Griffith BP, et al. Influence of hospital procedural volume on care process and mortality for patients undergoing elective surgery for mitral regurgitation. Circulation. 2007;115:881 7. 31. Vassileva CM, McNeely C, Spertus J, et al. Hospital volume, mitral repair rates, and mortality in mitral valve surgery in the elderly: an analysis of US hospitals treating Medicare fee-for-service patients. J Thorac Cardiovasc Surg. 2015;149:762 8, e1. 32. Chikwe J, Toyoda N, Anyanwu AC, et al. Relation of mitral valve sur- gery volume to repair rate, durability, and survival. J Am Coll Cardiol. 2017;69:2397 406. 33. Chhatriwalla AK, Vemulapalli S, Holmes DR Jr, et al. Institutional experi- ence with transcatheter mitral valve repair and clinical outcomes: insights from the TVT registry. JACC Cardiovasc Interv. 2019;12:1342 52. 34. Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist. 1970;10:20 30. 35. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489 95. 2.6. The Multidisciplinary Heart Valve Team and Heart Valve Centers 1. Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117 27. 2. Patel HJ, Herbert MA, Drake DH, et al. Aortic valve replacement: using a statewide cardiac surgical database identifies a procedural volume hinge point. Ann Thorac Surg. 2013;96:1560 5. 3. Dewey TM, Herbert MA, Ryan WH, et al. Influence of surgeon vol- ume on outcomes with aortic valve replacement. Ann Thorac Surg. 2012;93:1107 12. 4. McNeely C, Markwell S, Filson K, et al. Effect of hospital volume on pros- thesis use and mortality in aortic valve operations in the elderly. Ann Tho- rac Surg. 2016;101:585 90. 5. Khera R, Pandey A, Koshy T, et al. Role of hospital volumes in identifying low-performing and high-performing aortic and aitral valve surgical cen- ters in the United States. JAMA Cardiol. 2017;2:1322 31. 6. Carroll JD, Vemulapalli S, Dai D, et al. Procedural experience for transcath- eter aortic valve replacement and relation to outcomes: the STS/ACC TVT registry. J Am Coll Cardiol. 2017;70:29 41. CLINICAL STATEMENTS AND GUIDELINES 7. Bolling SF, Li S, O Brien SM, et al. Predictors of mitral valve repair: clinical and surgeon factors. Ann Thorac Surg. 2010;90:1904 11. 8. Chikwe J, Toyoda N, Anyanwu AC, et al. Relation of mitral valve sur- gery volume to repair rate, durability, and survival. J Am Coll Cardiol. 2017;69:2397 406. 9. Gammie JS, O Brien SM, Griffith BP, et al. Influence of hospital procedural volume on care process and mortality for patients undergoing elective surgery for mitral regurgitation. Circulation. 2007;115:881 7. 10. Kilic A, Shah AS, Conte JV, et al. Operative outcomes in mitral valve sur- gery: combined effect of surgeon and hospital volume in a population- based analysis. J Thorac Cardiovasc Surg. 2013;146:638 46. 11. Vassileva CM, Boley T, Markwell S, et al. Impact of hospital annual mitral procedural volume on mitral valve repair rates and mortality. J Heart Valve Dis. 2012;21:41 7. 12. Nishimura RA, O Gara PT, Bavaria JE, et al. 2019 AATS/ACC/ASE/SCAI/STS ex- pert consensus systems of care document: a proposal to optimize care for patients with valvular heart disease: a joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2019;73:2609 35. 13. Ando T, Adegbala O, Villablanca PA, et al. Failure to rescue, hospital vol- ume, and in-hospital mortality after transcatheter aortic valve implanta- tion. Am J Cardiol. 2018;122:828 32. 14. Edwards FH, Ferraris VA, Kurlansky PA, et al. Failure to rescue rates af- ter coronary artery bypass grafting: an analysis from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2016;102:458 64. 15. Scali ST, Giles KA, Kubilis P, et al. Impact of hospital volume on patient safety indicators and failure to rescue following open aortic aneurysm re- pair. J Vasc Surg. 2020;71:1135 46.e4. 16. Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and failure to res- cue with high-risk surgery. Med Care. 2011;49:1076 81. 17. Gonzalez AA, Dimick JB, Birkmeyer JD, et al. Understanding the volume- outcome effect in cardiovascular surgery: the role of failure to rescue. JAMA Surg. 2014;149:119 23. 18. Ward ST, Dimick JB, Zhang W, et al. Association between hospital staffing models and failure to rescue. Ann Surg. 2019;270:91 4. 19. Wakeam E, Asafu-Adjei D, Ashley SW, et al. The association of intensiv- ists with failure-to-rescue rates in outlier hospitals: results of a national survey of intensive care unit organizational characteristics. J Crit Care. 2014;29:930 5. 20. Holmes DR, Rich JB, Zoghbi WA, et al. The heart team of cardiovascular care. J Am Coll Cardiol. 2013;61:903 7. 2.7. Management of Patients With VHD After Valve Intervention 2.7.4. Periodic Imaging After Valve Intervention 1. Salaun E, Mahjoub H, Girerd N, et al. Rate, timing, correlates, and out- comes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement. Circulation. 2018;138:971 85. 2. Salaun E, Mahjoub H, Dahou A, et al. Hemodynamic deterioration of surgically implanted bioprosthetic aortic valves. J Am Coll Cardiol. 2018;72:241 51. 3. AORTIC STENOSIS 3.2.1. Diagnosis and Follow-Up 3.2.1.1. Diagnostic Testing: Initial Diagnosis 1. Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused up- date from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30:372 92. 2. Gardezi SKM, Myerson SG, Chambers J, et al. Cardiac auscultation poorly predicts the presence of valvular heart disease in asymptomatic primary care patients. Heart. 2018;104:1832 5. 3. Eleid MF, Michelena HI, Nkomo VT, et al. Causes of death and predic- tors of survival after aortic valve replacement in low flow vs. normal flow severe aortic stenosis with preserved ejection fraction. Eur Heart J Cardio- vasc Imaging. 2015;16:1270 5. 4. Kadem L, Dumesnil JG, Rieu R, et al. Impact of systemic hypertension on the assessment of aortic stenosis. Heart. 2005;91:354 61. 5. Laskey WK, Kussmaul WG 3rd. Hypertension, aortic valve stenosis, and the aorta: more lessons from TAVR. J Am Coll Cardiol. 2015;65:434 6. 6. Yotti R, Bermejo J, Guti rrez-Iba es E, et al. Systemic vascular load in cal- cific degenerative aortic valve stenosis: insight from percutaneous valve replacement. J Am Coll Cardiol. 2015;65:423 33. 7. Lindman BR, Otto CM. Time to treat hypertension in patients with aortic stenosis. Circulation. 2013;128:1281 3. 8. Lin SS, Roger VL, Pascoe R, et al. Dobutamine stress Doppler hemodynam- ics in patients with aortic stenosis: feasibility, safety, and surgical correla- tions. Am Heart J. 1998;136:1010 6. 9. Monin JL, Monchi M, Gest V, et al. Aortic stenosis with severe left ven- tricular dysfunction and low transvalvular pressure gradients: risk strati- fication by low-dose dobutamine echocardiography. J Am Coll Cardiol. 2001;37:2101 7. 10. Clavel M-A, Fuchs C, Burwash IG, et al. Predictors of outcomes in low- flow, low-gradient aortic stenosis: results of the multicenter TOPAS Study. Circulation. 2008;118:S234 42. 11. Otto CM, Pearlman AS, Comess KA, et al. Determination of the stenotic aortic valve area in adults using Doppler echocardiography. J Am Coll Car- diol. 1986;7:509 17. 12. Oh JK, Taliercio CP, Holmes DR, et al. Prediction of the severity of aor- tic stenosis by Doppler aortic valve area determination: prospective Doppler-catheterization correlation in 100 patients. J Am Coll Cardiol. 1988;11:1227 34. 13. Jander N, Hochholzer W, Kaufmann BA, et al. Velocity ratio predicts out- comes in patients with low gradient severe aortic stenosis and preserved EF. Heart. 2014;100:1946 53. 14. Pawade T, Clavel M-A, Tribouilloy C, et al. Computed tomography aortic valve calcium scoring in patients with aortic stenosis. Circ Cardiovasc Im- aging. 2018;11:e007146. 15. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611 7. 16. Messika-Zeitoun D, Aubry M-C, Detaint D, et al. Evaluation and clinical implications of aortic valve calcification measured by electron-beam com- puted tomography. Circulation. 2004;110:356 62. 17. Cueff C, Serfaty J-M, Cimadevilla C, et al. Measurement of aortic valve calcification using multislice computed tomography: correlation with hae- modynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart. 2011;97:721 6. 18. Clavel M-A, Pibarot P, Messika-Zeitoun D, et al. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. J Am Coll Cardiol. 2014;64:1202 13. 19. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr. 2009;10:1 25. 20. Currie PJ, Seward JB, Reeder GS, et al. Continuous-wave Doppler echocar- diographic assessment of severity of calcific aortic stenosis: a simultane- ous Doppler-catheter correlative study in 100 adult patients. Circulation. 1985;71:1162 9. 21. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptom- atic valvular aortic stenosis. Clinical, echocardiographic, and exercise pre- dictors of outcome. Circulation. 1997;95:2262 70. 22. Zoghbi WA, Farmer KL, Soto JG, et al. Accurate noninvasive quantifica- tion of stenotic aortic valve area by Doppler echocardiography. Circula- tion. 1986;73:452 9. 23. Otto CM, Pearlman AS. Doppler echocardiography in adults with symp- tomatic aortic stenosis. Diagnostic utility and cost-effectiveness. Arch In- tern Med. 1988;148:2553 60. 24. Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic steno- sis. Natural history and risk stratification by echocardiography. Eur Heart J. 2004;25:199 205. 25. Otto CM. Valvular stenosis. In: Otto CM, ed. The Textbook of Clinical Echocardiography. 6th ed. Philadelphia, PA: Elsevier; 2018:288 323. 26. Stewart RAH, Kerr AJ, Whalley GA, et al. Left ventricular systolic and dia- stolic function assessed by tissue Doppler imaging and outcome in asymp- tomatic aortic stenosis. Eur Heart J. 2010;31:2216 22. 27. Jander N, Minners J. Aortic stenosis: disease severity, progression, and timing and type of intervention. In: Otto CM, ed. The Practice of Clinical Echocardiography. 6th ed. Philadelphia, PA: Elsevier; 2021. In press. 28. Nishimura RA, Grantham JA, Connolly HM, et al. Low-output, low-gra- dient aortic stenosis in patients with depressed left ventricular systolic CLINICAL STATEMENTS AND GUIDELINES function: the clinical utility of the dobutamine challenge in the catheter- ization laboratory. Circulation. 2002;106:809 13. 29. Clavel MA, Webb JG, Rod s-Cabau J, et al. Comparison between trans- catheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction. Circulation. 2010;122:1928 36. 30. deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low trans- valvular gradients. Am J Cardiol. 1995;75:191 4. 31. Blais C, Burwash IG, Mundigler G, et al. Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low-flow, low-gradient aortic stenosis: the multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) study. Circulation. 2006;113:711 21. 32. Pibarot P, Dumesnil JG. Low-flow, low-gradient aortic stenosis with nor- mal and depressed left ventricular ejection fraction. J Am Coll Cardiol. 2012;60:1845 53. 33. Bradley SM, Foag K, Monteagudo K, et al. Use of routinely captured echocardiographic data in the diagnosis of severe aortic stenosis. Heart. 2019;105:112 6. 3.2.1.3. Diagnostic Testing: Routine Follow-Up 1. Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J Am Coll Car- diol. 1989;13:545 50. 2. Brener SJ, Duffy CI, Thomas JD, et al. Progression of aortic stenosis in 394 patients: relation to changes in myocardial and mitral valve dysfunction. J Am Coll Cardiol. 1995;25:305 10. 3. Roger VL, Tajik AJ, Bailey KR, et al. Progression of aortic stenosis in adults: new appraisal using Doppler echocardiography. Am Heart J. 1990;119:331 8. 4. Bahler RC, Desser DR, Finkelhor RS, et al. Factors leading to progression of valvular aortic stenosis. Am J Cardiol. 1999;84:1044 8. 5. Palta S, Pai AM, Gill KS, et al. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000;101:2497 502. 6. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611 7. 7. Rosseb AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with sim- vastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343 56. 8. Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of aortic stenosis in patients with benign aortic valve thickening. Arch Intern Med. 2002;162:2345 7. 9. Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not C-reactive pro- tein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol. 2007;50:1992 8. 10. Owens DS, Katz R, Takasu J, et al. Incidence and progression of aortic valve calcium in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Cardiol. 2010;105:701 8. 11. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic valves. JAMA. 2008;300:1317 25. 12. Michelena HI, Desjardins VA, Avierinos J-F, et al. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation. 2008;117:2776 84. 13. Lindman BR, Bonow RO, Otto CM. Current management of calcific aortic stenosis. Circ Res. 2013;113:223 37. 3.2.1.4. Diagnostic Testing: Cardiac Catheterization 1. Shavelle DM. Evaluation of valvular heart disease by cardiac catheriza- tion and angiocardiography. In: Otto CM, Bonow RO, eds. Valvular Heart Disease: A Companion to Braunwald s Heart Disease. 4th ed. Philadelphia, PA: Elsevier/Saunders; 2014:91 106. 2. Nishimura RA, Carabello BA. Hemodynamics in the cardiac catheterization laboratory of the 21st century. Circulation. 2012;125:2138 50. 3.2.1.5. Diagnostic Testing: Exercise Testing 1. Saeed S, Rajani R, Seifert R, et al. Exercise testing in patients with asymp- tomatic moderate or severe aortic stenosis. Heart. 2018;104:1836 42. 2. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J. 2005;26:1309 13. 3. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptom- atic valvular aortic stenosis. Clinical, echocardiographic, and exercise pre- dictors of outcome. Circulation. 1997;95:2262 70. 4. Mar chaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis. Eur Heart J. 2010;31:1390 7. 5. Atterh g JH, Jonsson B, Samuelsson R. Exercise testing: a prospective study of complication rates. Am Heart J. 1979;98:572 9. 6. Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J Am Coll Car- diol. 1989;13:545 50. 7. Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of quantita- tive exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation. 2005;112:I377 82. 8. Amato MC, Moffa PJ, Werner KE, et al. Treatment decision in asymptom- atic aortic valve stenosis: role of exercise testing. Heart. 2001;86:381 6. 9. Alborino D, Hoffmann JL, Fournet PC, et al. Value of exercise testing to evaluate the indication for surgery in asymptomatic patients with valvular aortic stenosis. J Heart Valve Dis. 2002;11:204 9. 10. Takeda S, Rimington H, Chambers J. Prediction of symptom-onset in aortic stenosis: a comparison of pressure drop/flow slope and haemodynamic measures at rest. Int J Cardiol. 2001;81:131 7. 11. Skalski J, Allison TG, Miller TD. The safety of cardiopulmonary exercise testing in a population with high-risk cardiovascular diseases. Circulation. 2012;126:2465 72. 12. Dhoble A, Sarano ME, Kopecky SL, et al. Safety of symptom-limited car- diopulmonary exercise testing in patients with aortic stenosis. Am J Med. 2012;125:704 8. 3.2.2. Medical Therapy 1. Nazarzadeh M, Pinho-Gomes A-C, Smith Byrne K, et al. Systolic blood pressure and risk of valvular heart disease: a mendelian randomization study. JAMA Cardiol. 2019;4:788 95. 2. Rahimi K, Mohseni H, Kiran A, et al. Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults. Eur Heart J. 2018;39:3596 603. 3. Nielsen OW, Sajadieh A, Sabbah M, et al. Assessing optimal blood pres- sure in patients with asymptomatic aortic valve stenosis: the Simvastatin Ezetimibe in Aortic Stenosis study (SEAS). Circulation. 2016;134:455 68. 4. Rosseb AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with sim- vastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343 56. 5. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of inten- sive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389 97. 6. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvas- tatin on progression of aortic stenosis: results of the Aortic Stenosis Pro- gression Observation: Measuring Effects Of Rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306 14. 7. Ochiai T, Saito S, Yamanaka F, et al. Renin-angiotensin system block- ade therapy after transcatheter aortic valve implantation. Heart. 2018;104:644 51. 8. Inohara T, Manandhar P, Kosinski AS, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA. 2018;320:2231 41. 9. O Brien KD, Zhao X-Q, Shavelle DM, et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med. 2004;52:185 91. 10. Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aor- tic Stenosis (SCOPE-AS). Am Heart J. 2004;147:E19. 11. Nadir MA, Wei L, Elder DHJ, et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol. 2011;58:570 6. 12. Rieck E, Cramariuc D, Boman K, et al. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events. Hyper- tension. 2012;60:90 7. 13. Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compli- ance impacts significantly on left ventricular afterload and function in aor- tic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol. 2005;46:291 8. CLINICAL STATEMENTS AND GUIDELINES 14. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554 61. 15. Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease 2011 update. Circulation. 2011;124:1783 91. 16. Hansson NH, Sorensen J, Harms HJ, et al. Metoprolol reduces hemody- namic and metabolic overload in asymptomatic aortic valve stenosis pa- tients: a randomized trial. Circ Cardiovasc Imaging. 2017;10:e006557. 17. Lindman BR, Zajarias A, Madrazo JA, et al. Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricu- lar function in patients with severe symptomatic aortic stenosis. Circula- tion. 2012;125:2353 62. 3.2.3. Timing of Intervention 1. Kapadia SR, Leon MB, Makkar RR, et al. 5-Year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2485 91. 2. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implanta- tion for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597 607. 3. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696 704. 4. Otto CM, Pearlman AS. Doppler echocardiography in adults with symp- tomatic aortic stenosis. Diagnostic utility and cost-effectiveness. Arch In- tern Med. 1988;148:2553 60. 5. Turina J, Hess O, Sepulcri F, et al. Spontaneous course of aortic valve dis- ease. Eur Heart J. 1987;8:471 83. 6. Kelly TA, Rothbart RM, Cooper CM, et al. Comparison of outcome of asymptomatic to symptomatic patients older than 20 years of age with valvular aortic stenosis. Am J Cardiol. 1988;61:123 30. 7. Pellikka PA, Nishimura RA, Bailey KR, et al. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol. 1990;15:1012 7. 8. Dahl JS, Eleid MF, Michelena HI, et al. Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic ste- nosis undergoing aortic valve replacement. Circ Cardiovasc Imaging. 2015;8:e002917. 9. Taniguchi T, Morimoto T, Shiomi H, et al. Prognostic impact of left ven- tricular ejection fraction in patients with severe aortic stenosis. JACC Car- diovasc Interv. 2018;11:145 57. 10. Ito S, Miranda WR, Nkomo VT, et al. Reduced left ventricular ejec- tion fraction in patients with aortic stenosis. J Am Coll Cardiol. 2018;71:1313 21. 11. Bohbot Y, de Meester de Ravenstein C, Chadha G, et al. Relationship be- tween left ventricular ejection fraction and mortality in asymptomatic and minimally symptomatic patients with severe aortic stenosis. JACC Cardio- vasc Imaging. 2019;12:38 48. 12. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611 7. 13. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptom- atic valvular aortic stenosis. Clinical, echocardiographic, and exercise pre- dictors of outcome. Circulation. 1997;95:2262 70. 14. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during pro- longed follow-up. Circulation. 2005;111:3290 5. 15. Lancellotti P, Donal E, Magne J, et al. Risk stratification in asymptomatic moderate to severe aortic stenosis: the importance of the valvular, arterial and ventricular interplay. Heart. 2010;96:1364 71. 16. Kang D-H, Park S-J, Rim JH, et al. Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation. 2010;121:1502 9. 17. Tribouilloy C, L vy F, Rusinaru D, et al. Outcome after aortic valve re- placement for low-flow/low-gradient aortic stenosis without contrac- tile reserve on dobutamine stress echocardiography. J Am Coll Cardiol. 2009;53:1865 73. 18. Herrmann HC, Pibarot P, Hueter I, et al. Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a Placement of Aortic Transcatheter Valves (PARTNER) trial analysis. Circulation. 2013;127:2316 26. 19. Anjan VY, Herrmann HC, Pibarot P, et al. Evaluation of flow after trans- catheter aortic valve replacement in patients with low-flow aortic stenosis: a secondary analysis of the PARTNER randomized clinical trial. JAMA Car- diol. 2016;1:584 92. 20. Lopez-Marco A, Miller H, Youhana A, et al. Low-flow low-gradient aortic stenosis: surgical outcomes and mid-term results after isolated aortic valve replacement. Eur J Cardiothorac Surg. 2016;49:1685 90. 21. O Sullivan CJ, Englberger L, Hosek N, et al. Clinical outcomes and revascu- larization strategies in patients with low-flow, low-gradient severe aortic valve stenosis according to the assigned treatment modality. JACC Cardio- vasc Interv. 2015;8:704 17. 22. Nishimura RA, Grantham JA, Connolly HM, et al. Low-output, low-gradi- ent aortic stenosis in patients with depressed left ventricular systolic func- tion: the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation. 2002;106:809 13. 23. Monin J-L, Qu r J-P, Monchi M, et al. Low-gradient aortic stenosis: op- erative risk stratification and predictors for long-term outcome: a mul- ticenter study using dobutamine stress hemodynamics. Circulation. 2003;108:319 24. 24. Foug res E, Tribouilloy C, Monchi M, et al. Outcomes of pseudo-severe aortic stenosis under conservative treatment. Eur Heart J. 2012;33:2426 33. 25. Eleid MF, Padang R, Al-Hijji M, et al. Hemodynamic response in low-flow low-gradient aortic stenosis with preserved ejection fraction after TAVR. J Am Coll Cardiol. 2019;73:1731 2. 26. Rusinaru D, Bohbot Y, Ringle A, et al. Impact of low stroke volume on mortality in patients with severe aortic stenosis and preserved left ven- tricular ejection fraction. Eur Heart J. 2018;39:1992 9. 27. Zheng Q, Djohan AH, Lim E, et al. Effects of aortic valve replacement on severe aortic stenosis and preserved systolic function: systematic review and network meta-analysis. Sci Rep. 2017;7:5092. 28. Mar chaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis. Eur Heart J. 2010;31:1390 7. 29. Saeed S, Mancia G, Rajani R, et al. Exercise treadmill testing in moderate or severe aortic stenosis: the left ventricular correlates of an exaggerated blood pressure rise. J Am Heart Assoc. 2018;7:e010735. 30. Saeed S, Rajani R, Seifert R, et al. Exercise testing in patients with asymp- tomatic moderate or severe aortic stenosis. Heart. 2018;104:1836 42. 31. Kang D-H, Park S-J, Lee S-A, et al. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med. 2020;382:111 9. 32. Nakatsuma K, Taniguchi T, Morimoto T, et al. B-type natriuretic peptide in patients with asymptomatic severe aortic stenosis. Heart. 2019;105:384 90. 33. Lancellotti P, Magne J, Dulgheru R, et al. Outcomes of patients with as- ymptomatic aortic stenosis followed up in heart valve clinics. JAMA Car- diol. 2018;3:1060 8. 34. Taniguchi T, Morimoto T, Shiomi H, et al. Sudden death in patients with severe aortic stenosis: observations from the CURRENT AS registry. J Am Heart Assoc. 2018;7:e008397. 35. Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic stenosis. Circulation. 2010;121:151 6. 36. Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symp- tom-free survival and postoperative outcome in severe aortic stenosis. Circulation. 2004;109:2302 8. 37. Gerber IL, Stewart RAH, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 2003;107:1884 90. 38. Lim P, Monin JL, Monchi M, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J. 2004;25:2048 53. 39. Taniguchi T, Morimoto T, Shiomi H, et al. Initial surgical versus conservative strategies in patients with asymptomatic severe aortic stenosis. J Am Coll Cardiol. 2015;66:2827 38. 40. Nishimura S, Izumi C, Nishiga M, et al. Predictors of rapid progression and clinical outcome of asymptomatic severe aortic stenosis. Circ J. 2016;80:1863 9. 41. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: patho- genesis, disease progression, and treatment strategies. Circulation. 2005;111:3316 26. 42. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J. 1988;9(suppl E):57 64. 43. Kvidal P, Bergstr m R, H rte LG, et al. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol. 2000;35:747 56. CLINICAL STATEMENTS AND GUIDELINES 44. Murphy ES, Lawson RM, Starr A, et al. Severe aortic stenosis in patients 60 years of age or older: left ventricular function and 10-year survival after valve replacement. Circulation. 1981;64:II184 8. 45. O Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Sur- geons 2008 cardiac surgery risk models: part 2 isolated valve surgery. Ann Thorac Surg. 2009;88:S23 42. 46. Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replace- ment on survival. Circulation. 1982;66:1105 10. 47. Oh JK, Taliercio CP, Holmes DR, et al. Prediction of the severity of aor- tic stenosis by Doppler aortic valve area determination: prospective Doppler-catheterization correlation in 100 patients. J Am Coll Cardiol. 1988;11:1227 34. 48. Galan A, Zoghbi WA, Qui ones MA. Determination of severity of valvular aortic stenosis by Doppler echocardiography and relation of findings to clinical outcome and agreement with hemodynamic measurements deter- mined at cardiac catheterization. Am J Cardiol. 1991;67:1007 12. 49. Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic steno- sis. Natural history and risk stratification by echocardiography. Eur Heart J. 2004;25:199 205. 50. Stewart RAH, Kerr AJ, Whalley GA, et al. Left ventricular systolic and dia- stolic function assessed by tissue Doppler imaging and outcome in asymp- tomatic aortic stenosis. Eur Heart J. 2010;31:2216 22. 51. Rosseb AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with sim- vastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343 56. 52. Kennedy KD, Nishimura RA, Holmes DR Jr, et al. Natural history of moder- ate aortic stenosis. J Am Coll Cardiol. 1991;17:313 9. 53. Jander N, Minners J, Holme I, et al. Outcome of patients with low-gradi- ent severe aortic stenosis and preserved ejection fraction. Circulation. 2011;123:887 95. 54. Saito T, Muro T, Takeda H, et al. Prognostic value of aortic valve area in- dex in asymptomatic patients with severe aortic stenosis. Am J Cardiol. 2012;110:93 7. 55. Pereira JJ, Lauer MS, Bashir M, et al. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. J Am Coll Cardiol. 2002;39:1356 63. 56. Clavel MA, Webb JG, Rod s-Cabau J, et al. Comparison between trans- catheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction. Circulation. 2010;122:1928 36. 57. Connolly HM, Oh JK, Orszulak TA, et al. Aortic valve replacement for aor- tic stenosis with severe left ventricular dysfunction. Prognostic indicators. Circulation. 1997;95:2395 400. 58. Qu r J-P, Monin J-L, Levy F, et al. Influence of preoperative left ventricular contractile reserve on postoperative ejection fraction in low-gradient aor- tic stenosis. Circulation. 2006;113:1738 44. 59. Pai RG, Varadarajan P, Razzouk A. Survival benefit of aortic valve re- placement in patients with severe aortic stenosis with low ejection frac- tion and low gradient with normal ejection fraction. Ann Thorac Surg. 2008;86:1781 9. 60. Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for low-flow/ low-gradient aortic stenosis operative risk stratification and long-term out- come: a European multicenter study. J Am Coll Cardiol. 2008;51:1466 72. 61. Gotzmann M, Lindstaedt M, Bojara W, et al. Clinical outcome of trans- catheter aortic valve implantation in patients with low-flow, low gradient aortic stenosis. Catheter Cardiovasc Interv. 2012;79:693 701. 62. Pereira JJ, Balaban K, Lauer MS, et al. Aortic valve replacement in patients with mild or moderate aortic stenosis and coronary bypass surgery. Am J Med. 2005;118:735 42. 63. Smith WT, Ferguson TB Jr, Ryan T, et al. Should coronary artery bypass graft surgery patients with mild or moderate aortic stenosis undergo con- comitant aortic valve replacement? A decision analysis approach to the surgical dilemma. J Am Coll Cardiol. 2004;44:1241 7. 64. Gillinov AM, Garcia MJ. When is concomitant aortic valve replacement indicated in patients with mild to moderate stenosis undergoing coronary revascularization? Curr Cardiol Rep. 2005;7:101 4. 65. Bhattacharyya S, Hayward C, Pepper J, et al. Risk stratification in as- ymptomatic severe aortic stenosis: a critical appraisal. Eur Heart J. 2012;33:2377 87. 66. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr. 2009;10:1 25. 67. deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low trans- valvular gradients. Am J Cardiol. 1995;75:191 4. 68. Tarantini G, Covolo E, Razzolini R, et al. Valve replacement for severe aor- tic stenosis with low transvalvular gradient and left ventricular ejection fraction exceeding 0.50. Ann Thorac Surg. 2011;91:1808 15. 69. Clavel M-A, Dumesnil JG, Capoulade R, et al. Outcome of patients with aortic stenosis, small valve area, and low-flow, low-gradient de- spite preserved left ventricular ejection fraction. J Am Coll Cardiol. 2012;60:1259 67. 70. Lancellotti P, Magne J, Donal E, et al. Clinical outcome in asymptomatic se- vere aortic stenosis: insights from the new proposed aortic stenosis grad- ing classification. J Am Coll Cardiol. 2012;59:235 43. 71. Mehrotra P, Jansen K, Flynn AW, et al. Differential left ventricular remodel- ling and longitudinal function distinguishes low flow from normal-flow preserved ejection fraction low-gradient severe aortic stenosis. Eur Heart J. 2013;34:1906 14. 72. Lauten J, Rost C, Breithardt OA, et al. Invasive hemodynamic characteris- tics of low gradient severe aortic stenosis despite preserved ejection frac- tion. J Am Coll Cardiol. 2013;61:1799 808. 73. Mangner N, Stachel G, Woitek F, et al. Predictors of mortality and symp- tomatic outcome of patients with low-flow severe aortic stenosis under- going transcatheter aortic valve replacement. J Am Heart Assoc. 2018;7: e010287. 74. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38: 2739 91. 75. Ozkan A, Hachamovitch R, Kapadia SR, et al. Impact of aortic valve re- placement on outcome of symptomatic patients with severe aortic ste- nosis with low gradient and preserved left ventricular ejection fraction. Circulation. 2013;128:622 31. 76. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvas- tatin on progression of aortic stenosis: results of the Aortic Stenosis Pro- gression Observation: Measuring Effects Of Rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306 14. 77. Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of quantita- tive exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation. 2005;112:I377 82. 78. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J. 2005;26:1309 13. 79. Alborino D, Hoffmann JL, Fournet PC, et al. Value of exercise testing to evaluate the indication for surgery in asymptomatic patients with valvular aortic stenosis. J Heart Valve Dis. 2002;11:204 9. 80. Takeda S, Rimington H, Chambers J. Prediction of symptom-onset in aortic stenosis: a comparison of pressure drop/flow slope and haemodynamic measures at rest. Int J Cardiol. 2001;81:131 7. 81. Skalski J, Allison TG, Miller TD. The safety of cardiopulmonary exercise testing in a population with high-risk cardiovascular diseases. Circulation. 2012;126:2465 72. 82. Dayan V, Vignolo G, Magne J, et al. Outcome and impact of aortic valve replacement in patients with preserved LVEF and low-gradient aortic ste- nosis. J Am Coll Cardiol. 2015;66:2594 603. 3.2.4. Choice of Intervention 3.2.4.1. Choice of Mechanical Versus Bioprosthetic AVR 1. Goldstone AB, Chiu P, Baiocchi M, et al. Mechanical or biologic pros- theses for aortic-valve and mitral-valve replacement. N Engl J Med. 2017;377:1847 57. 2. Badhwar V, Ofenloch JC, Rovin JD, et al. Noninferiority of closely moni- tored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients. Ann Thorac Surg. 2012;93:748 53. 3. Brown ML, Schaff HV, Lahr BD, et al. Aortic valve replacement in patients aged 50 to 70 years: improved outcome with mechanical versus biologic prostheses. J Thorac Cardiovasc Surg. 2008;135:878 84. 4. van Geldorp MWA, Eric Jamieson WR, Kappetein AP, et al. Patient out- come after aortic valve replacement with a mechanical or biological pros- thesis: weighing lifetime anticoagulant-related event risk against reopera- tion risk. J Thorac Cardiovasc Surg. 2009;137:881 6, 866.e1 5. 5. Kulik A, B dard P, Lam B-K, et al. Mechanical versus bioprosthetic valve replacement in middle-aged patients. Eur J Cardiothorac Surg. 2006;30:485 91. 6. Glaser N, Jackson V, Holzmann MJ, et al. Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50 69 years. Eur Heart J. 2016;37:2658 67. CLINICAL STATEMENTS AND GUIDELINES 7. Chikwe J, Chiang YP, Egorova NN, et al. Survival and outcomes following bioprosthetic vs mechanical mitral valve replacement in patients aged 50 to 69 years. JAMA. 2015;313:1435 42. 8. McClure RS, McGurk S, Cevasco M, et al. Late outcomes comparison of nonelderly patients with stented bioprosthetic and mechanical valves in the aortic position: a propensity-matched analysis. J Thorac Cardiovasc Surg. 2014;148:1931 9. 9. Chiang YP, Chikwe J, Moskowitz AJ, et al. Survival and long-term out- comes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA. 2014;312:1323 9. 10. Kaneko T, Aranki S, Javed Q, et al. Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 2014;147:117 26. 11. Buratto E, Shi WY, Wynne R, et al. Improved survival after the Ross pro- cedure compared with mechanical aortic valve replacement. J Am Coll Cardiol. 2018;71:1337 44. 12. El-Hamamsy I, Eryigit Z, Stevens L-M, et al. Long-term outcomes after autograft versus homograft aortic root replacement in adults with aortic valve disease: a randomised controlled trial. Lancet. 2010;376:524 31. 13. Martin E, Mohammadi S, Jacques F, et al. Clinical outcomes following the Ross procedure in adults: a 25-year longitudinal study. J Am Coll Cardiol. 2017;70:1890 9. 14. Bourguignon T, Bouquiaux-Stablo A-L, Loardi C, et al. Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bio- prosthesis: 25-year follow-up of 450 implantations. J Thorac Cardiovasc Surg. 2014;148:2004 11.e1. 15. Bourguignon T, El Khoury R, Candolfi P, et al. Very long-term outcomes of the Carpentier-Edwards PERIMOUNT aortic valve in patients aged 60 or younger. Ann Thorac Surg. 2015;100:853 9. 16. Tuzcu EM, Kapadia SR, Vemulapalli S, et al. Transcatheter aortic valve re- placement of failed surgically implanted bioprostheses: the STS/ACC reg- istry. J Am Coll Cardiol. 2018;72:370 82. 17. Ye J, Cheung A, Yamashita M, et al. Transcatheter aortic and mitral valve- in-valve implantation for failed surgical bioprosthetic valves: an 8-year single-center experience. JACC Cardiovasc Interv. 2015;8:1735 44. 18. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312:162 70. 19. Dvir D, Webb J, Brecker S, et al. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in- valve registry. Circulation. 2012;126:2335 44. 20. Coylewright M, Forrest JK, McCabe JM, et al. TAVR in low-risk patients: FDA approval, the new NCD, and shared decision-making. J Am Coll Car- diol. 2020;75:1208 11. 21. Hess EP, Coylewright M, Frosch DL, et al. Implementation of shared deci- sion making in cardiovascular care: past, present, and future. Circ Cardio- vasc Qual Outcomes. 2014;7:797 803. 22. Weber A, Noureddine H, Englberger L, et al. Ten-year comparison of peri- cardial tissue valves versus mechanical prostheses for aortic valve replace- ment in patients younger than 60 years of age. J Thorac Cardiovasc Surg. 2012;144:1075 83. 23. Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36:1152 8. 24. Chan V, Jamieson WRE, Germann E, et al. Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related com- plications to 15 years after aortic valve replacement. J Thorac Cardiovasc Surg. 2006;131:1267 73. 25. Dunning J, Gao H, Chambers J, et al. Aortic valve surgery: marked increas- es in volume and significant decreases in mechanical valve use an analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Sur- gery in Great Britain and Ireland National database. J Thorac Cardiovasc Surg. 2011;142:776 82.e3. 26. Stassano P, L. DT, Monaco M, et al. Aortic valve replacement: a prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years. J Am Coll Cardiol. 2009;54:1862 8. 27. Brennan JM, Edwards FH, Zhao Y, et al. Long-term safety and effective- ness of mechanical versus biologic aortic valve prostheses in older pa- tients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. Circulation. 2013;127:1647 55. 28. Banbury MK, Cosgrove DM 3rd, Thomas JD, et al. Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg. 2002;73:1460 5. 29. Dellgren G, David TE, Raanani E, et al. Late hemodynamic and clinical out- comes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg. 2002;124:146 54. 30. Borger MA, Ivanov J, Armstrong S, et al. Twenty-year results of the Han- cock II bioprosthesis. J Heart Valve Dis. 2006;15:49 55. 31. Myk n PSU, Bech-Hansen O. A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg. 2009;137:76 81. 32. Mazine A, El-Hamamsy I, Verma S, et al. Ross procedure in adults for car- diologists and cardiac Surgeons: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:2761 77. 3.2.4.2. Choice of SAVR Versus TAVI for Patients for Whom a Bioprosthetic AVR Is Appropriate 1. Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgi- cal aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. BMJ. 2016;354:i5130. 2. Foroutan F, Guyatt GH, O Brien K, et al. Prognosis after surgical replace- ment with a bioprosthetic aortic valve in patients with severe symptom- atic aortic stenosis: systematic review of observational studies. BMJ. 2016;354:i5065. 3. Siontis GCM, Overtchouk P, Cahill TJ, et al. Transcatheter aortic valve im- plantation vs. surgical aortic valve replacement for treatment of symp- tomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 2019;40:3143 53. 4. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replace- ment with a self-expanding prosthesis. N Engl J Med. 2014;370:1790 8. 5. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aor- tic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2477 84. 6. Deeb GM, Reardon MJ, Chetcuti S, et al. 3-Year outcomes in high-risk pa- tients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;67:2565 74. 7. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609 20. 8. Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve re- placement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387:2218 25. 9. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replace- ment with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695 705. 10. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve re- placement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706 15. 11. Siontis KC, Killu AM. Silent and non-silent thromboembolic events after ventricular tachycardia ablation: modifiable risk with postprocedure anti- coagulation? J Cardiovasc Electrophysiol. 2019;30:1197 9. 12. Kapadia SR, Leon MB, Makkar RR, et al. 5-Year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2485 91. 13. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replace- ment using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972 81. 14. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implanta- tion for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597 607. 15. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes af- ter transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686 95. 16. Burke CR, Kirkpatrick JN, Otto CM. Goals of care in patients with severe aortic stenosis. Eur Heart J. 2020;41:929 32. 17. Otto CM. 